bulk drug substances; prohibitions

Summary

The bill makes it illegal to sell or distribute compounded medications that contain GLP‑1 receptor agonists or similar obesity‑treatment substances unless the bulk ingredients meet detailed FDA‑approved and pharmacopeial standards. It also forces manufacturers and wholesalers to provide verification and testing documentation, requires record‑keeping and board inspections, and imposes civil fines and possible license loss for violations.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share